Gynecologic Oncology

Latest News

January 20th 2021

Dr. Coleman on the Potential of Tisotumab Vedotin in Cervical Cancer

By Robert L. Coleman, MD, FACOG, FACS

Robert L. Coleman, MD, FACOG, FACS, discusses the potential of tisotumab vedotin in cervical cancer.

January 20th 2021

HPV-Negative Cervical Cancer: Myth or An Area to Therapeutically Tackle?

By Gina Mauro

January 18th 2021

Dr. Markman on Remaining Questions With HPV- Cervical Cancer

By Maurie Markman, MD

January 18th 2021

Dr. Coleman on Moving Immunotherapy Into Earlier Treatment Lines in Cervical Cancer

By Robert L. Coleman, MD, FACOG, FACS

January 11th 2021

Questions Remain Regarding PARP Inhibition in Recurrent Platinum-Sensitive Ovarian Cancer

By Brittany Cote

Latest Videos

Dr. Leath on the Results of the GOG 240 Trial in Advanced Cervical Cancer

Dr. Backes on Next Steps for Lenvatinib and Weekly Paclitaxel in Endometrial Cancer

Dr. Ferguson on the Impact of the LACC Trial Data on Cervical Cancer Surgery

Dr. Hong on Moving Tisotumab Vedotin to Frontline Therapy for Cervical Cancer

Dr. Backes on Rationale for Lenvatinib and Weekly Paclitaxel in Endometrial Cancer

Dr. Coleman on the Use of Immunotherapy in Cervical Cancer

Dr. Oaknin on the Rationale for the GARNET Trial in Endometrial Cancer

Dr. Yadav on the Olaparib/Neratinib Combo in HER2+ Uterine Serous Carcinoma

Dr. Moore on Unanswered Questions With PARP Inhibitors in Ovarian Cancer

The Future of Managing Gynecologic Cancer

CME Content

Video

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

Marla D. Lipsyc-Sharf, MD; Ashley Frith, MD

Video

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

Video

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

Video

Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers

Zev A. Wainberg, MD; Manish A. Shah, MD, FASCO; Syma Iqbal, MD

Video

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Kentucky Society of Clinical Oncology

Marla D. Lipsyc-Sharf, MD; Munaf Alkadimi, MD

Video

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Indiana Oncology Society

Shaina Rozell, MD, MPH; Seth A. Wander, MD, PhD

In-Person Event

19th Annual New York GU Cancers Congress™

March 13-14, 2026

Register now!

Video

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Jennifer R. Brown, MD, PhD; Alexey V. Danilov, MD, PhD; Matthew S. Davids, MD, MMSc

Video

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Stephen V. Liu, MD; Michelle Afkhami, MD; Ignacio I. Wistuba, MD; Helena Yu, MD

In-Person + Virtual Event

Medical Crossfire® – From Diagnostic Dilemmas to Potential Treatment Breakthroughs: Exploring Novel Targets for Extrapulmonary Neuroendocrine Carcinomas

March 24, 2026

Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Ghassan Abou-Alfa, MD, MBA

Multimedia

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Hope S. Rugo, MD, FASCO; Neil M. Iyengar, MD; Komal Jhaveri, MD, FACP

Multimedia

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Yana G. Najjar, MD; Douglas B. Johnson, MD, MSCI; Rahul A. Sheth, MD, FSIR

Video

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

John H. Strickler, MD; Stacey A. Cohen, MD; Aparna Parikh, MD; Kanwal P.S. Raghav, MBBS, MD

Video

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Rebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhD

Video

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Jonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Video

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Gail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHS

Video

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MS

Video

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

$Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma$

Video

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Rami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MD

Video

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | South Carolina

Misty D. Shields, MD, PhD; Rujul Parikh, MD

Video

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kansas

Charu Aggarwal, MD, MPH, FASCO; Yifan Tu, MD, PhD

Video

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Wyoming and Montana

Charu Aggarwal, MD, MPH, FASCO; Mo Ziari, MD

Video

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | New Mexico

Zofia Piotrowska, MD, MHS; Shan Guo, MD

Video

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | North Carolina

Misty D. Shields, MD, PhD; Michelle Ojemuyiwa, MD

In-Person + Virtual Event

Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck – Post-CRT Decisions in the Locally Advanced Setting

February 19, 2026

Multimedia

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Video

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Shubham Pant, MD, MBBS

Video

Proactive Adverse Event Management for HER2+ BTC Treatments

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Rachna T. Shroff, MD, MS, FASCO

Video

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCR

Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Balazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MD

Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Eileen M. O’Reilly, MD; E. Gabriela Chiorean, MD, FASCO; Michael J. Pishvaian, MD, PhD; Brian Wolpin, MD, MPH

Video

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

More News

Rachel N. Grisham, MD, of Memorial Sloan Kettering Cancer Center

RAF/MEK Inhibitor VS-6766 Plus Defactinib Under Exploration in Recurrent Low-Grade Serous Ovarian Cancer

ByKristi Rosa

January 6th 2021

January 6, 2021 — The oral small molecule inhibitor VS-6766, developed by Verastem Oncology, is now under investigation alone and in combination with the FAK inhibitor defactinib in a recently initiated, registration-directed, phase 2 trial in patients with recurrent low-grade serous ovarian cancer.

Boehringer Ingelheim Looks to Expand Targeted Therapies Portfolio

ByBrittany Lovely

January 5th 2021

January 5, 2020 - Boehringer Ingelheim will add to its cancer cell-directed therapies portfolio with the acquisition of NBE-Therapeutics, the developer of NBE-002, an anti-ROR1 antibody-drug conjugate.

Bradley Corr, MD, of University of Colorado School of Medicine

Dr. Corr on the Rationale to Evaluate WNT Inhibition in Gynecologic Cancers

ByBradley Corr, MD

January 4th 2021

Bradley Corr, MD, discusses the rationale to evaluate WNT pathway inhibition in gynecologic cancers.

Future of Advanced Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Novel Targets for Advanced Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Endometrial Cancer: Chemo-Free Regimens on the Horizon

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Emerging Agents: Treatment of Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Sequencing for Advanced Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Recurrent Endometrial Cancer: Safety of Combination Therapy

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Combination Therapy for Recurrent Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Emerging ICI Therapy for Advanced Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Immune Checkpoint Inhibitors in Advanced Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

GOG-258 and PORTEC-3 Studies in Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

GOG-249 Study in Early-Stage Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

GOG 0209 Study in Advanced Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Role of Biomarker Testing in Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Risk Classification of Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Overview of Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Phuong L. Mai, MD, of University of Pittsburgh Medical Center Hillman Cancer Center

Pinpointing the Need for Genetic Testing in Oncology

ByCaroline Seymour

December 31st 2020

Phuong L. Mai, MD, discusses the situations in which genetic testing should be considered and the importance of bridging awareness and access within oncology.

Immunotherapy Combos Take Next Step in Gynecologic Cancers

ByErica DiNapoli

December 29th 2020

R. Wendel Naumann, MD, discusses numerous investigations of PD-1 inhibitors in combination with PARP inhibitors or other targeted agents, as well as chemotherapy, and how it could finally start the next chapter of immunotherapy in gynecologic malignancies.

Rucaparib Significantly Improves PFS Over Chemo in Later-Line, BRCA+ Ovarian Cancer

ByKristi Rosa

December 21st 2020

December 21, 2020 - Rucaparib was found to result in a statistically significant improvement in progression-free survival compared with chemotherapy in patients with BRCA-mutant ovarian cancer who had previously received 2 or more lines of chemotherapy.

Allison M. Puechlm, MD, Levine Cancer Institute, Atrium Health

Weighing Risks and Benefits Is Critical With Second-Line Maintenance PARP Inhibition in Ovarian Cancer

ByJessica Hergert

December 19th 2020

Allison M. Puechl, MD, discusses the role of second-line maintenance therapy in patients with recurrent ovarian cancer and considerations that may limit the accessibility of PARP inhibitors in this space.

The combination of pembrolizumab and lenvatinib has led to a statistically significant improvement in overall survival, progression-free survival, and objective response rate compared with chemotherapy in patients with advanced endometrial cancer who have received previous systemic treatment, meeting the dual primary end points and secondary end point of the phase 3 KEYNOTE-775 trial.

Pembrolizumab/Lenvatinib Combo Improves Survival, Responses Over Chemo in Advanced Endometrial Cancer

ByKristi Rosa

December 16th 2020

December 16, 2020 - Pembrolizumab/lenvatinib has significantly improved survival and responses compared with chemotherapy in patients with advanced endometrial cancer who have received previous systemic treatment.

Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute

Dr. Matulonis on the Need to Improve Immunotherapy Responses in Gynecologic Cancers

ByUrsula A. Matulonis, MD

December 8th 2020

Ursula A. Matulonis, MD, discusses the need to improve responses to immunotherapy among patients with recurrent gynecologic cancers.

BLA Submission for Balstilimab in Recurrent/Metastatic Cervical Cancer Delayed

ByKristi Rosa

December 4th 2020

December 4, 2020 - The completion of the biologics license application for balstilimab in the treatment of patients with recurrent or metastatic cervical cancer has been delayed to the first half of 2021.

Gynecologic Oncology

Latest News

Latest Videos

Dr. Leath on the Results of the GOG 240 Trial in Advanced Cervical Cancer

Dr. Backes on Next Steps for Lenvatinib and Weekly Paclitaxel in Endometrial Cancer

Dr. Ferguson on the Impact of the LACC Trial Data on Cervical Cancer Surgery

Dr. Hong on Moving Tisotumab Vedotin to Frontline Therapy for Cervical Cancer

Dr. Backes on Rationale for Lenvatinib and Weekly Paclitaxel in Endometrial Cancer

Dr. Coleman on the Use of Immunotherapy in Cervical Cancer

Dr. Oaknin on the Rationale for the GARNET Trial in Endometrial Cancer

Dr. Yadav on the Olaparib/Neratinib Combo in HER2+ Uterine Serous Carcinoma

Dr. Moore on Unanswered Questions With PARP Inhibitors in Ovarian Cancer

The Future of Managing Gynecologic Cancer

CME Content

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Kentucky Society of Clinical Oncology

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Indiana Oncology Society

19th Annual New York GU Cancers Congress™

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Medical Crossfire® – From Diagnostic Dilemmas to Potential Treatment Breakthroughs: Exploring Novel Targets for Extrapulmonary Neuroendocrine Carcinomas

Addressing Unmet Needs in HER2+ Metastatic BTC

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | South Carolina

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kansas

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Wyoming and Montana

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | New Mexico

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | North Carolina

Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck – Post-CRT Decisions in the Locally Advanced Setting

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Proactive Adverse Event Management for HER2+ BTC Treatments

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

More News

RAF/MEK Inhibitor VS-6766 Plus Defactinib Under Exploration in Recurrent Low-Grade Serous Ovarian Cancer

Boehringer Ingelheim Looks to Expand Targeted Therapies Portfolio

Dr. Corr on the Rationale to Evaluate WNT Inhibition in Gynecologic Cancers

Future of Advanced Endometrial Cancer

Novel Targets for Advanced Endometrial Cancer

Endometrial Cancer: Chemo-Free Regimens on the Horizon

Emerging Agents: Treatment of Endometrial Cancer

Sequencing for Advanced Endometrial Cancer

Recurrent Endometrial Cancer: Safety of Combination Therapy

Combination Therapy for Recurrent Endometrial Cancer

Emerging ICI Therapy for Advanced Endometrial Cancer

Immune Checkpoint Inhibitors in Advanced Endometrial Cancer

GOG-258 and PORTEC-3 Studies in Endometrial Cancer

GOG-249 Study in Early-Stage Endometrial Cancer

GOG 0209 Study in Advanced Endometrial Cancer

Role of Biomarker Testing in Endometrial Cancer

Risk Classification of Endometrial Cancer

Overview of Endometrial Cancer

Pinpointing the Need for Genetic Testing in Oncology

Immunotherapy Combos Take Next Step in Gynecologic Cancers

Rucaparib Significantly Improves PFS Over Chemo in Later-Line, BRCA+ Ovarian Cancer

Weighing Risks and Benefits Is Critical With Second-Line Maintenance PARP Inhibition in Ovarian Cancer

Pembrolizumab/Lenvatinib Combo Improves Survival, Responses Over Chemo in Advanced Endometrial Cancer

Dr. Matulonis on the Need to Improve Immunotherapy Responses in Gynecologic Cancers

BLA Submission for Balstilimab in Recurrent/Metastatic Cervical Cancer Delayed

Trending on OncLive

Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma

Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma

FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL

FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care